{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Renal+Cell+Carcinoma&page=7", "query": { "condition": "Stage IV Renal Cell Carcinoma", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 418, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Renal+Cell+Carcinoma&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Renal+Cell+Carcinoma&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T05:02:30.728Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00060307", "title": "Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Renal Cell Cancer", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2003-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-10-20T05:02:30.728Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060307" }, { "nct_id": "NCT06265285", "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Esophageal Squamous Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Esophageal Carcinoma", "Gastroesophageal Junction Adenocarcinoma", "Hepatocellular Carcinoma", "Locally Advanced Urothelial Carcinoma", "Lung Non-Small Cell Carcinoma", "Malignant Solid Neoplasm", "Metastatic Colorectal Carcinoma", "Metastatic Cutaneous Melanoma", "Metastatic Esophageal Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Esophageal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Unresectable Cutaneous Melanoma", "Unresectable Esophageal Squamous Cell Carcinoma", "Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Home Health Encounter", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-04-30", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-20T05:02:30.728Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06265285" }, { "nct_id": "NCT00458484", "title": "Radiosurgery in Treating Patients With Kidney Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "stereotactic radiosurgery", "type": "RADIATION" }, { "name": "Renal Biopsy", "type": "PROCEDURE" }, { "name": "Serum Blood Markers", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2007-02-20", "completion_date": "2019-09-12", "has_results": true, "last_update_posted_date": "2020-07-22", "last_synced_at": "2026-10-20T05:02:30.728Z", "location_count": 3, "location_summary": "Cleveland, Ohio • Orange, Ohio • Westlake, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Orange", "state": "Ohio" }, { "city": "Westlake", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00458484" }, { "nct_id": "NCT01590069", "title": "Aerosolized Aldesleukin in Treating Patients With Lung Metastases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Malignant Neoplasm in the Lung", "Metastatic Melanoma", "Metastatic Osteosarcoma", "Metastatic Renal Cell Cancer", "Sarcoma", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Osteosarcoma AJCC v7", "Stage IV Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Aerosolized Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 70, "start_date": "2012-06-28", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-20T05:02:30.728Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01590069" }, { "nct_id": "NCT00005069", "title": "Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2001-07", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-20T05:02:30.728Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005069" }, { "nct_id": "NCT00089362", "title": "Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Gastric Cancer", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Melanoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Ovarian Epithelial Cancer", "Recurrent Prostate Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Basal Cell Carcinoma of the Lip", "Stage III Colon Cancer", "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage III Gastric Cancer", "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Lymphoepithelioma of the Oropharynx", "Stage III Melanoma", "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Melanoma", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Ovarian Epithelial Cancer", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "alvespimycin hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-10", "last_synced_at": "2026-10-20T05:02:30.728Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089362" }, { "nct_id": "NCT00278395", "title": "Vorinostat in Treating Patients With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Renal Cell Carcinoma", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2005-10", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-10-20T05:02:30.728Z", "location_count": 2, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00278395" }, { "nct_id": "NCT00033956", "title": "Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "IL-2 Induced Hypotension" ], "interventions": [ { "name": "M40403", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MetaPhore Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-20T05:02:30.728Z", "location_count": 3, "location_summary": "Chicago, Illinois • Portland, Oregon • Salt Lake City, Utah", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Oregon" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033956" }, { "nct_id": "NCT00276536", "title": "Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Kidney Cancer", "Lymphoma", "Melanoma", "Multiple Myeloma", "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "recombinant interferon alpha-1b", "type": "BIOLOGICAL" }, { "name": "IFN", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 35, "start_date": "2001-01", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2015-10-14", "last_synced_at": "2026-10-20T05:02:30.728Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00276536" }, { "nct_id": "NCT04429321", "title": "Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Renal Cell Carcinoma Stage IV" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "bland embolization", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2020-08-26", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2024-04-26", "last_synced_at": "2026-10-20T05:02:30.728Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04429321" } ] }